The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.
about
Infection of cells expressing CXCR4 mutants lacking N-glycosylation at the N-terminal extracellular domain is enhanced for R5X4-dualtropic human immunodeficiency virus type-1.Structural analysis of the HIV-1 gp120 V3 loop: application to the HIV-Haiti isolates.A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsVariants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycanTwo N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domainMapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.Resistance of human immunodeficiency virus type 1 to the high-mannose binding agents cyanovirin N and concanavalin A.Adaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated regionThe V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.Identification of two N-linked glycosylation sites within the core of the simian immunodeficiency virus glycoprotein whose removal enhances sensitivity to soluble CD4.Partial enzymatic deglycosylation preserves the structure of cleaved recombinant HIV-1 envelope glycoprotein trimers.Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable regionStructure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.A single injection of recombinant measles virus vaccines expressing human immunodeficiency virus (HIV) type 1 clade B envelope glycoproteins induces neutralizing antibodies and cellular immune responses to HIV.Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies.HIV-1 envelope glycan moieties modulate HIV-1 transmission.Effect of B-cell depletion on coreceptor switching in R5 simian-human immunodeficiency virus infection of rhesus macaques.The Broad Neutralizing Antibody Responses after HIV-1 Superinfection Are Not Dominated by Antibodies Directed to Epitopes Common in Single InfectionCoreceptor switch in R5-tropic simian/human immunodeficiency virus-infected macaquesImmunogenicity of virus-like particles containing modified human immunodeficiency virus envelope proteinsIsolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.High-mannose-specific deglycosylation of HIV-1 gp120 induced by resistance to cyanovirin-N and the impact on antibody neutralization.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine DesignCharacterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.R5X4 viruses are evolutionary, functional, and antigenic intermediates in the pathway of a simian-human immunodeficiency virus coreceptor switchGlycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regionsMultiple Antibody Lineages in One Donor Target the Glycan-V3 Supersite of the HIV-1 Envelope Glycoprotein and Display a Preference for Quaternary Binding.Elicitation of broadly reactive antibodies against glycan-modulated neutralizing V3 epitopes of HIV-1 by immune complex vaccines.Human immunodeficiency virus-1 gp120 V3 loop for anti-acquired immune deficiency syndrome drug discovery: computer-aided approaches to the problem solving.Broadly Neutralizing Antibodies against HIV-1 As a Novel Aspect of the Immune Response.Different HIV-1 env frames: gp120 and ASP (antisense protein) biosynthesis, and theirs co-variation tropic amino acid signatures in X4- and R5-viruses.Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.
P2860
Q24794092-DA5A91B4-F45F-4718-AFEB-AFC140CEF2F3Q31112947-C29B0C97-7C54-41B3-98B1-96902D909E82Q31143293-55C2B8DF-13B6-4B7F-B2E1-33BA0ED538B7Q33558676-8061AC96-9D1F-4159-B3D0-3B62F8C1F86CQ33685141-EB745923-31EF-4404-A51E-4A3B378F8A04Q33707333-8E856A3C-702F-43C5-834F-758911A5839EQ33826682-F3017666-4563-4884-870A-F286EB110F39Q33841935-B658CF51-50D9-44AA-8E1C-E203E150F379Q33841969-A50C0995-3DCC-4F15-8D2D-AFA1A4CB8EE1Q33842989-3DD15CB2-C235-40C5-B776-24E545BE0C2EQ33870292-198C3307-EA1D-4349-8020-8E398BFB1962Q33883936-15852F62-75FC-491B-9E31-C346FB5BA66FQ33984371-6B1D8E8A-654A-4B80-A3F2-A373E37A1DF9Q34285680-A1706E83-72A2-4A70-96D8-BBED04EC7CF7Q34464860-7C93EFD5-361E-446E-A415-951A78D7DF55Q34471760-9A9C17F7-D67D-4B57-A83F-389102DC8012Q34499013-7DAD7FAC-FBF4-4E13-BA01-B7C6578D024DQ34551010-83A19F4E-EFC3-4CEE-92FC-ADF92AE557FDQ34552313-8F3134DF-A98B-4476-9D0E-89B93EFED5A6Q34553676-29DDF311-4C16-40A4-95E6-CF40755DBF29Q34595009-ADE8B90C-DF5A-4B7F-98EB-02EA871E5F74Q34742696-0D6C224A-CF0B-4F9E-9C61-300EDE0166CAQ35686970-69196723-DE40-4BFD-88AD-A2B40C3E8751Q35947758-C0BFD644-40B2-49CA-A41E-4A752306847FQ35985896-DC80DE02-B3BE-4CBC-9835-3ECCD7D9B64CQ36103090-F9F4E093-897D-4CC1-B317-6912931A529FQ36174694-28A14879-5B6D-49DA-BA22-1877F7936BE2Q36237904-70EF0A2D-7328-4378-9C9D-AFC8AD8A7626Q36447540-DAB9632E-09FB-49DE-B5B6-4BA5E3FE698EQ36673173-25810BA0-6DD4-4F84-8CDC-F1A16C2FE2DDQ36747765-85A577A7-F048-4619-8638-BE4D1130CC84Q36994698-95D24797-E927-486D-836A-D685DC4D6BC1Q37010852-C184AAEF-AF25-45E7-AAC4-DCA8E675B420Q37099851-42CB8C3A-65AC-45B3-BA80-8A041E4A6D6EQ37415418-863F1305-25F8-4A78-B6BD-164031AF500FQ37419234-674E5CF6-7F4E-4436-B407-F5E96FC75D8CQ38014473-AC3DB8BC-9A9E-42BA-9CB2-B2D80F7CC32DQ38707583-6BA8E3C6-567C-453B-B626-F723F9B80D86Q38973543-4F845709-B2B8-4C28-BD2F-D6DD34187B41Q39193318-34D4C532-291F-401E-9352-FB3A9F389F4A
P2860
The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
The N-terminal V3 loop glycan ...... h CD4 and chemokine receptors.
@en
The N-terminal V3 loop glycan ...... h CD4 and chemokine receptors.
@nl
type
label
The N-terminal V3 loop glycan ...... h CD4 and chemokine receptors.
@en
The N-terminal V3 loop glycan ...... h CD4 and chemokine receptors.
@nl
prefLabel
The N-terminal V3 loop glycan ...... h CD4 and chemokine receptors.
@en
The N-terminal V3 loop glycan ...... h CD4 and chemokine receptors.
@nl
P2093
P2860
P1433
P1476
The N-terminal V3 loop glycan ...... h CD4 and chemokine receptors.
@en
P2093
C Cheng-Mayer
J Robinson
L Cavacini
S E Malenbaum
P2860
P304
11008-11016
P356
10.1128/JVI.74.23.11008-11016.2000
P407
P577
2000-12-01T00:00:00Z